HFA Premium Access

HDAC6 inhibition reduces cardiac fibrosis, enhances mitochondrial function and demonstrates comparable efficacy as empagliflozin in a mouse model of heart failure with preserved ejection fraction

Topic: Heart Failure with Preserved Ejection Fraction (HFpEF)

Congress Presentation

About the speaker

Mr Jin Yang

Tenaya Therapeutics, South San Francisco (United States of America)
0 follower

32 more presentations in this session

Comparison 8 vs. 10mm fenestration size of the atrial flow regulator in patients with heart failure with reduced and preserved ejection fraction: an analysis of the Prelieve Trial

Speaker: Doctor C. Paitazoglou (Luebeck, DE)


Improved vascular function after ventricular assist device implantation

Speaker: Doctor D. Nebunu (Zurich, CH)


Left-heart reverse remodeling patterns following treatment with sacubitril/valsartan

Speaker: Doctor A. Abboud (Boston, US)


Identifying distinct clinical subgroups in heart failure with mildly reduced ejection fraction

Speaker: Assistant Professor A. Uijl (Amsterdam, NL)


The impact of intravenous ferric carboxymaltose on echocardiographic markers of cardiac function in patients with HFrEF and cardiac implantable electronic devices: sub-analysis of the RESAFE-HF trial

Speaker: Doctor C. Bakogiannis (Thessaloniki, GR)


Access the full session

Heart Failure ePosters - focus on Chronic Heart Failure 5

Speakers: Mr J. Yang, Doctor C. Paitazoglou, Doctor D. Nebunu, Doctor A. Abboud, Assistant Professor A. Uijl...

About the event


Heart Failure 2022

21 May - 24 May 2022

Sessions Presentations

ESC 365 is supported by